priors.science/reviews/chronic-kidney-disease-management

Chronic Kidney Disease Management

The current evidence on 51 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

51claims tracked
161primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
14 Established · 21 Likely · 14 Uncertain · 2 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Erythropoiesis-stimulating agents increase haemoglobin in chronic kidney diseaseAnaemia CKDEstablished93%10
Calcimimetics reduce parathyroid hormone in chronic kidney disease-mineral and bone disorderCKD MBDEstablished92%16
Angiotensin-converting enzyme inhibitors slow chronic kidney disease in proteinuriaRaas BlockadeEstablished92%11
SGLT2 composite kidney outcomes in chronic kidney diseaseSglt2 CKDEstablished92%18
Phosphate binders reduce serum phosphateCKD MBDEstablished90%12
Finerenone reduces urine albumin-to-creatinine ratio in chronic kidney diseaseFinerenone CKDEstablished90%19
Angiotensin receptor blockers slow chronic kidney disease in diabetic nephropathyRaas BlockadeEstablished90%10
High haemoglobin targets with erythropoiesis-stimulating agents raise cardiovascular risk in chronic kidney diseaseAnaemia CKDEstablished88%11
High FGF-23 predicts cardiovascular mortality in chronic kidney diseaseCKD MBDEstablished88%12
Finerenone reduces chronic kidney disease progression in type 2 diabetesFinerenone CKDEstablished87%17
Hypoxia-inducible factor prolyl hydroxylase inhibitors non-inferior to erythropoiesis-stimulating agents in chronic kidney diseaseAnaemia CKDEstablished86%11
Finerenone: cardiovascular events in diabetic chronic kidney diseaseFinerenone CKDEstablished86%22
Semaglutide slows chronic kidney disease progressionGlp1 CKDEstablished86%13
SGLT2 reduces albuminuria in chronic kidney diseaseSglt2 CKDEstablished85%15
GLP-1 agonists reduce albuminuria in chronic kidney diseaseGlp1 CKDLikely84%12
SGLT2: heart failure hospitalisation in chronic kidney diseaseSglt2 CKDLikely83%12
GLP-1 agonists cut cardiovascular events in chronic kidney diseaseGlp1 CKDLikely82%12
SGLT2 kidney outcomes in non-diabetic chronic kidney diseaseSglt2 CKDLikely82%16
Low bicarbonate predicts chronic kidney disease progressionMetabolic Acidosis CKDLikely80%10
Roxadustat for chronic kidney disease anaemia on dialysisAnaemia CKDLikely80%11
Renin-angiotensin-aldosterone system antiproteinuric effect beyond blood pressureRaas BlockadeLong-standingLikely80%10
Statins reduce major adverse cardiovascular events in non-dialysis chronic kidney diseaseStatins CKDLikely80%9
High phosphate predicts cardiovascular death in chronic kidney diseaseCKD MBDLong-standingLikely79%11
Dual renin-angiotensin-aldosterone system blockade increases chronic kidney disease harmRaas BlockadeLong-standingLikely79%10
Vitamin D analogues reduce parathyroid hormone in chronic kidney diseaseCKD MBDLong-standingLikely78%14
Intensive blood pressure reduces cardiovascular events in chronic kidney diseaseBlood Pressure CKDLikely77%13
Blood pressure lowering reduces mortality in chronic kidney diseaseBlood Pressure CKDLong-standingLikely77%10
Finerenone beyond renin-angiotensin-aldosterone system blockade in chronic kidney diseaseFinerenone CKDLikely77%12
SGLT2 slows estimated glomerular filtration rate loss in advanced chronic kidney diseaseSglt2 CKDLikely76%12
Hypoxia-inducible factor prolyl hydroxylase inhibitors improve iron utilisation in chronic kidney diseaseAnaemia CKDLikely75%10
Sodium bicarbonate slows chronic kidney disease in acidosisMetabolic Acidosis CKDLikely73%10
Intensive blood pressure lowers proteinuria in chronic kidney diseaseBlood Pressure CKDLong-standingLikely73%9
Alkali therapy preserves muscle mass in chronic kidney diseaseMetabolic Acidosis CKDLikely72%10
Hyperuricaemia predicts chronic kidney disease progressionUric Acid CKDLikely72%11
Semaglutide slows estimated glomerular filtration rate decline in chronic kidney diseaseGlp1 CKDLikely71%10
Finerenone plus SGLT2 inhibitors in chronic kidney diseaseFinerenone CKDUncertain66%17
SGLT2: cardiovascular death in chronic kidney diseaseSglt2 CKDUncertain64%13
GLP-1 agonists: direct kidney protectionGlp1 CKDUncertain63%11
Statins lower all-cause mortality in chronic kidney diseaseStatins CKDUncertain62%10
Low-density lipoprotein below 70 reduces cardiovascular events in chronic kidney diseaseStatins CKDUncertain61%9
Higher serum bicarbonate slows chronic kidney diseaseMetabolic Acidosis CKDUncertain60%10
Non-calcium binders lower mortality in chronic kidney diseaseCKD MBDLong-standingUncertain60%12
Statins: limited benefit in dialysis chronic kidney diseaseStatins CKDUncertain58%9
Dietary acid reduction slows chronic kidney diseaseMetabolic Acidosis CKDUncertain56%10
Intensive blood pressure slows chronic kidney disease progressionBlood Pressure CKDLong-standingUncertain55%10
Intensive blood pressure increases acute kidney injury risk in chronic kidney diseaseBlood Pressure CKDLong-standingUncertain55%9
Stopping angiotensin-converting enzyme inhibitors in advanced chronic kidney diseaseRaas BlockadeLong-standingUncertain55%10
Finerenone in non-diabetic chronic kidney diseaseFinerenone CKDUncertain52%12
Allopurinol does not slow chronic kidney diseaseUric Acid CKDUncertain52%10
Febuxostat does not slow chronic kidney disease progressionUric Acid CKDDoubtful48%10
Urate-lowering therapy reduces kidney failureUric Acid CKDDoubtful40%11
Track Chronic Kidney Disease Management.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.